Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD00295 ...
Drug Name Morphine
Molecular Weight 285.3377
Molecular Formula C17H19NO3
CAS Number 57-27-2
SMILES [H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O
External Links
DRUGBANK DB00295
T3DB T3D2740
PubChem Compound 5288826
PDR 1134
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Log P 0.87 - 0.87 - Agilent Technology. LC/MS/MS Analysis of Opiates.
Boiling Point 190.0 ℃ 190 ℃ Lide DR. CRC Handbook of Chemistry. 2004
Melting Point 255.0 ℃ 255 ℃ MSDS
Water Solubility 149.0 mg/L 149 mg/L MSDS
pKa 8.21 - 8.21 - Agilent Technology. LC/MS/MS Analysis of Opiates.

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
AUC 73.5 ng.h/ml 225-290 nmol.h/L PO, oral; DRUGBANK
Bioavailability 90.0 % 80-100 % PO, oral; DRUGBANK
Bioavailability 24.0 % 24±12 % PO, oral; The Pharmacological Basis of Therapeutics
Bioavailability 100.0 % ~100 % IM,intramuscular injection; The Pharmacological Basis of Therapeutics
C Max 80.8 ng/ml 283.0 nmol/L PO, oral; DRUGBANK
C Max 70.0 ng/ml ~70 ng/ml IM,intramuscular injection; The Pharmacological Basis of Therapeutics
C Max 10.0 ng/ml 10.0 ng/ml PO, oral; immediate release formulation; The Pharmacological Basis of Therapeutics
C Max 7.4 ng/ml 7.4 ng/ml PO, oral; Sustained Release formulation; The Pharmacological Basis of Therapeutics
C Max 300.0 ng/ml 200-400 ng/ml The Pharmacological Basis of Therapeutics
T Max 1.5 h 1.5 h PO, oral; DRUGBANK
T Max 0.25 h 0.2-0.3 h IM,intramuscular injection; The Pharmacological Basis of Therapeutics
T Max 1.0 h 0.5-1.5 h PO, oral; immediate release formulation; The Pharmacological Basis of Therapeutics
T Max 5.5 h 3-8 h PO, oral; Sustained Release formulation; The Pharmacological Basis of Therapeutics
Tss 36.0 h 24-48 h PO, oral; DRUGBANK
Metabolic 90.0 % 90 % DRUGBANK
Clearance 96.0 L/h 1600.0 ml/min intravenous injection, IV; subcutaneous injection, SC; DRUGBANK
Clearance 1.4 L/h/kg 24±10 ml/min/kg Elderly → ;Children → ;Neonates ↓ ;Prem, premature ↓ ;Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia ↓ ;Burn ↓ ; The Pharmacological Basis of Therapeutics
Clearance 1.6 L/h/kg 26 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 5.3 L/kg 5.31 L/kg DRUGBANK
Volume of Distribution 3.6 L/kg 3.61 L/kg DRUGBANK
Volume of Distribution 3.3 L/kg 3.3±0.9 L/kg Neonates → ;Hepatic cirrhosis, cirr → ;Hepatic cirrhosis, cirr ↓ ; The Pharmacological Basis of Therapeutics
Volume of Distribution 2.3 L/kg 2.3 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 2.5 h 2-3 h DRUGBANK
Half-life 1.9 h 1.9±0.5 h Children → ;Neonates ↑ ;Prem, premature ↑ ;Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia → ; The Pharmacological Basis of Therapeutics
Half-life 4.0 h 4.0±1.5 h Active metabolite; The Pharmacological Basis of Therapeutics
Half-life 50.0 h 50±37 h The Pharmacological Basis of Therapeutics
Half-life 2.0 h 2 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Toxicity LD50 0.78 mg/L 0.78 ug/ml Male, men; DRUGBANK
Toxicity LD50 0.98 mg/L 0.98 ug/ml  Female, women; DRUGBANK
Toxicity LD50 461.0 mg/kg 461.0 mg/kg PO, oral; Rattus, Rat; T3DB
Toxicity LD50 600.0 mg/kg 600.0 mg/kg PO, oral; mouse; T3DB
Toxicity Lethal Dose 185.0 mg 120-250 mg human, homo sapiens; T3DB
Eliminate Route 8.5 % 7-10 % Faeces excretion; DRUGBANK
Eliminate Route 6.0 % 2-10 % Urinary excretion; Unchanged drug; DRUGBANK
Eliminate Route 4.0 % 4±5 % Urinary excretion; PO, oral; Unchanged drug; The Pharmacological Basis of Therapeutics
Eliminate Route 14.0 % 14±7 % Urinary excretion; IM,intramuscular injection; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 35.0 % 35 % DRUGBANK
Protein Binding 35.0 % 35±2 % acute viral hepatitis AVH ↓ ;Hepatic cirrhosis, cirr ↓ ;hypoalbuminemia Alb ↓ ; The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for children 0.2 mg/kg/dose 0.2 mg/kg/dose PO, oral Duramorph morphine sulfate PDR
Max dose for children 4.0 mg/dose 4 mg/dose PO, oral Duramorph morphine sulfate PDR
Max dose for children 0.8 mg/kg/day 0.8 mg/kg/day PO, oral Duramorph morphine sulfate PDR
Max dose for children 16.0 mg/day 16 mg/day PO, oral Duramorph morphine sulfate PDR
Max dose for adolescents 0.2 mg/kg/dose 0.2 mg/kg/dose PO, oral Duramorph morphine sulfate PDR
Max dose for adolescents 4.0 mg/dose 4 mg/dose PO, oral Duramorph morphine sulfate PDR
Max dose for adolescents 0.8 mg/kg/day 0.8 mg/kg/day PO, oral Duramorph morphine sulfate PDR
Max dose for adolescents 16.0 mg/day 16 mg/day PO, oral Duramorph morphine sulfate PDR
Max dose for adults 1600.0 mg/day 1600 mg/day Capsule, PO, Oral Duramorph morphine sulfate PDR
Max dose for adults 15.0 mg/dose 15 mg/dose epidural administration Duramorph morphine sulfate PDR
Max dose for adults 6.0 mg/dose 6 mg/dose PO, oral Duramorph morphine sulfate PDR
Max dose for adults 24.0 mg/day 24 mg/day PO, oral Duramorph morphine sulfate PDR
Max dose for adults 4.0 mg/dose 4 mg/dose PO, oral Duramorph morphine sulfate PDR
Max dose for adults 16.0 mg/day 16 mg/day PO, oral Duramorph morphine sulfate PDR
Max dose for geriatric 1600.0 mg/day 1600 mg/day Capsule, PO, Oral Duramorph morphine sulfate PDR
Max dose for geriatric 15.0 mg/dose 15 mg/dose epidural administration Duramorph morphine sulfate PDR
Max dose for geriatric 6.0 mg/dose 6 mg/dose PO, oral Duramorph morphine sulfate PDR
Max dose for geriatric 24.0 mg/day 24 mg/day PO, oral Duramorph morphine sulfate PDR
Max dose for geriatric 4.0 mg/dose 4 mg/dose PO, oral Duramorph morphine sulfate PDR
Max dose for geriatric 16.0 mg/day 16 mg/day PO, oral Duramorph morphine sulfate PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1